Jan Van den Bossche holds a Master Degree in Applied Economic Sciences at the KULeuven. He worked for more than 12 years as a biotech analyst at Petercam. He was involved in numerous public and private transactions of Belgian and Dutch Biotech companies, such as ThromboGenics, Tigenix, UCB, AMT (Uniqure), IBA, MDxHealth . Before he joined Fund+, he was for more than 2 years part of the investor relations team at the Dutch life sciences and materials sciences company DSM (Geleen, NL). He serves on the board of Octimet, Aelin Therapeutics and Immunic Inc.